Valvanera Fernández-Laso1, Cristina Sastre1, Jose M Valdivielso2, Angels Betriu2, Elvira Fernández2, Jesús Egido1, Jose L Martín-Ventura1, Luis M Blanco-Colio3. 1. Vascular Research Laboratory, Fundación Jiménez Díaz University Hospital-Health Research Institute, Madrid, Spain; and. 2. Unit for Detection and Treatment of Atherothrombotic Diseases, Experimental Nephrology Laboratory, Arnau de Vilanova University Hospital, Biomedical Research Institute of Lleida, Lleida, Spain. 3. Vascular Research Laboratory, Fundación Jiménez Díaz University Hospital-Health Research Institute, Madrid, Spain; and lblanco@fjd.es.
Abstract
BACKGROUND AND OBJECTIVES: Soluble TNF-like weak inducer of apoptosis (sTWEAK) is a proinflammatory cytokine belonging to the TNF superfamily. sTWEAK concentrations have been associated with the presence of CKD and cardiovascular disease (CVD). We hypothesized that sTWEAK levels may relate to a higher prevalence of atherosclerotic plaques, vascular calcification, and cardiovascular outcomes observed in patients with CKD. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: A 4-year prospective, multicenter, longitudinal study was conducted in 1058 patients with CKD stages 3-5D (mean age =58±13 years old; 665 men) but without any history of CVD from the NEFRONA Study (a study design on the prevalence of surrogate markers of CVD). Ankle-brachial index and B-mode ultrasound were performed to detect the presence of carotid and/or femoral atherosclerotic plaques together with biochemical measurements and sTWEAK assessment. Patients were followed for cardiovascular outcomes (follow-up of 3.13±1.15 years). RESULTS: Patients with more advanced CKD had lower sTWEAK levels. sTWEAK concentrations were independently and negatively associated with carotid intima-media thickness. sTWEAK levels were lower in patients with carotid atherosclerotic plaques but not in those with femoral plaques. After adjustment by confounders, the odds ratio (OR) for presenting carotid atherosclerotic plaques in patients in the lowest versus highest tertile of sTWEAK was 4.18 (95% confidence interval [95% CI], 2.89 to 6.08; P<0.001). Furthermore, sTWEAK levels were lower in patients with calcified carotid atherosclerotic plaques. The OR for presenting calcified carotid plaques was 1.77 (95% CI, 1.06 to 2.93; P=0.02) after multivariable adjustment. After the follow-up, 41 fatal and 68 nonfatal cardiovascular events occurred. In a Cox model, after controlling for potential confounding factors, patients in the lowest tertile of sTWEAK concentrations had a higher risk of fatal and nonfatal cardiovascular events (hazard ratio [HR], 2.40; 95% CI, 1.33 to 4.33; P=0.004) and cardiovascular mortality (HR, 2.67; 95% CI, 1.05 to 6.76; P=0.04). CONCLUSIONS: Low sTWEAK levels were associated with the presence of carotid atherosclerotic plaques in patients with CKD. Additionally, lower sTWEAK levels were associated with a higher risk of cardiovascular morbidity and mortality.
BACKGROUND AND OBJECTIVES: Soluble TNF-like weak inducer of apoptosis (sTWEAK) is a proinflammatory cytokine belonging to the TNF superfamily. sTWEAK concentrations have been associated with the presence of CKD and cardiovascular disease (CVD). We hypothesized that sTWEAK levels may relate to a higher prevalence of atherosclerotic plaques, vascular calcification, and cardiovascular outcomes observed in patients with CKD. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: A 4-year prospective, multicenter, longitudinal study was conducted in 1058 patients with CKD stages 3-5D (mean age =58±13 years old; 665 men) but without any history of CVD from the NEFRONA Study (a study design on the prevalence of surrogate markers of CVD). Ankle-brachial index and B-mode ultrasound were performed to detect the presence of carotid and/or femoral atherosclerotic plaques together with biochemical measurements and sTWEAK assessment. Patients were followed for cardiovascular outcomes (follow-up of 3.13±1.15 years). RESULTS:Patients with more advanced CKD had lower sTWEAK levels. sTWEAK concentrations were independently and negatively associated with carotid intima-media thickness. sTWEAK levels were lower in patients with carotid atherosclerotic plaques but not in those with femoral plaques. After adjustment by confounders, the odds ratio (OR) for presenting carotid atherosclerotic plaques in patients in the lowest versus highest tertile of sTWEAK was 4.18 (95% confidence interval [95% CI], 2.89 to 6.08; P<0.001). Furthermore, sTWEAK levels were lower in patients with calcified carotid atherosclerotic plaques. The OR for presenting calcified carotid plaques was 1.77 (95% CI, 1.06 to 2.93; P=0.02) after multivariable adjustment. After the follow-up, 41 fatal and 68 nonfatal cardiovascular events occurred. In a Cox model, after controlling for potential confounding factors, patients in the lowest tertile of sTWEAK concentrations had a higher risk of fatal and nonfatal cardiovascular events (hazard ratio [HR], 2.40; 95% CI, 1.33 to 4.33; P=0.004) and cardiovascular mortality (HR, 2.67; 95% CI, 1.05 to 6.76; P=0.04). CONCLUSIONS: Low sTWEAK levels were associated with the presence of carotid atherosclerotic plaques in patients with CKD. Additionally, lower sTWEAK levels were associated with a higher risk of cardiovascular morbidity and mortality.
Authors: J M de Bray; J M Baud; P Delanoy; J P Camuzat; V Dehans; J Descamp-Le Chevoir; J R Launay; F Luizy; Y Sentou; P Cales Journal: Cerebrovasc Dis Date: 1998 Sep-Oct Impact factor: 2.762
Authors: Valvanera Fernández-Laso; Cristina Sastre; Jose M Valdivielso; Elvira Fernández; Jose L Martín-Ventura; Jesús Egido; Luis M Blanco-Colio Journal: Atherosclerosis Date: 2015-02-07 Impact factor: 5.162
Authors: P-J Touboul; M G Hennerici; S Meairs; H Adams; P Amarenco; M Desvarieux; S Ebrahim; M Fatar; R Hernandez Hernandez; S Kownator; P Prati; T Rundek; A Taylor; N Bornstein; L Csiba; E Vicaut; K S Woo; F Zannad Journal: Cerebrovasc Dis Date: 2004-11-02 Impact factor: 2.762
Authors: Joseph F Polak; Michael J Pencina; Karol M Pencina; Christopher J O'Donnell; Philip A Wolf; Ralph B D'Agostino Journal: N Engl J Med Date: 2011-07-21 Impact factor: 91.245
Authors: Jonas Axelsson; Holger Jon Møller; Anna Witasp; Abdul Rashid Qureshi; Juan Jesus Carrero; Olof Heimbürger; Peter Bárány; Anders Alvestrand; Bengt Lindholm; Søren K Moestrup; Peter Stenvinkel Journal: Am J Kidney Dis Date: 2006-12 Impact factor: 8.860
Authors: Ioana Potrovita; Wen Zhang; Linda Burkly; Kyungmin Hahm; John Lincecum; Monica Z Wang; Martin H Maurer; Moritz Rossner; Armin Schneider; Markus Schwaninger Journal: J Neurosci Date: 2004-09-22 Impact factor: 6.167
Authors: Emmanuel Chorianopoulos; Mark Rosenberg; Christian Zugck; Johanna Wolf; Hugo A Katus; Norbert Frey Journal: Eur J Heart Fail Date: 2009-11 Impact factor: 15.534
Authors: Christina Pachel; Denise Mathes; Barbara Bayer; Charlotte Dienesch; Gaby Wangorsch; Wolfram Heitzmann; Isabell Lang; Hossein Ardehali; Georg Ertl; Thomas Dandekar; Harald Wajant; Stefan Frantz Journal: PLoS One Date: 2013-11-11 Impact factor: 3.240